Aurobindo Pharma Q4 Net Profit Rises 2 pc to Rs.921 Cr

Hyderabad, May 21 (TNT): Aurobindo Pharma Limited on Thursday reported a consolidated net profit of Rs.921 crore for the fourth quarter ended March 31, 2026, registering a 2 per cent increase compared to Rs.903 crore reported in the corresponding quarter of the previous financial year.

The Hyderabad-based pharmaceutical major reported revenue from operations of Rs.8,853 crore during the quarter, up 5.6 per cent year-on-year from Rs.8,382 crore.

For the full financial year FY26, the company’s revenue from operations rose 6.1 per cent to Rs.33,653 crore, the pharma company said in a release.

EBITDA before forex and other income stood at Rs.1,801 crore for the quarter, while EBITDA margin was reported at 20.3 per cent.

The company said its European business crossed the milestone of €1 billion in annual revenues during FY26. Europe revenues for the quarter increased by 30.2 per cent year-on-year to Rs.2,795 crore, driven by strong performance across key markets.

Growth Markets revenue increased by 24.7 per cent to Rs.980 crore, while Anti-Retroviral (ARV) business revenue rose 6.4 per cent to Rs.328 crore during the quarter.

However, US formulations revenue declined by 13 per cent year-on-year to Rs.3,543 crore due to lower transient sales, though it continued to account for 40 per cent of consolidated revenue.

Aurobindo Pharma said it received final approval for nine ANDAs from the USFDA during the quarter and launched 12 products in the US market.

The company has cumulatively filed 888 ANDAs with the USFDA and received 728 final approvals as of March 31, 2026.

Commenting on the performance, K. Nithyananda Reddy said the company remained encouraged by its operational resilience, strong product portfolio and improved efficiencies.

He said consistent volumes, operating discipline and investments in capacity expansion and recently commercialised facilities would support sustainable long-term growth.

TNT TS